Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

HPV Infection Clinical Trial

— Add-Vacc  

Official title:

Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04953130
• Other study ID #: MITU-003
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: August 1, 2022
• Est. completion date: October 2026

Study information

• Verified date: October 2023
• Source: London School of Hygiene and Tropical Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to a multi-year cohort of boys (intervention arm). The CRT will be conducted in 26 communities/clusters (13 per arm) in northern Tanzania. Boys aged 14 to 18 years in the intervention arm will receive one dose of the 4-valent HPV vaccine (Gardasil®) that protects against HPV 6, 11, 16, and 18. Population genital HPV prevalence in 18 to 21-year-olds will be compared between intervention clusters (female and male vaccination) and control clusters (female vaccination only) at 3 years after the intervention. Blood sampling for immune responses and adverse event data collection will be performed in a subset of 200 male subjects in selected intervention clusters.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10400
• Est. completion date: October 2026
• Est. primary completion date: November 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 14 Years to 18 Years

Eligibility

Inclusion Criteria:

• Parents and adult male participants (aged 18 years) must sign an ICF and male participants aged less than 18 years must sign an informed assent form (IAF), indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and to receive HPV vaccination. If the parent or participant cannot read or write, the procedures must be explained and informed consent/assent must be witnessed by a literate third party who is not involved in the conduct of the study.

• Participants must have been born male, and must be aged 14 to 18 years inclusive at time of vaccination.

• Participants must be living in an intervention community (cluster).

• Participants must be willing and able to comply with the protocol requirements.

• Participants must agree to avoid all non-trial immunisations in the 14 days following vaccination with the trial vaccine, other than emergency vaccinations such as post-exposure rabies or tetanus vaccinations.

• Participants must be healthy as determined by a medical history. A physical examination will be conducted if necessary according to the clinician's judgement.

Exclusion Criteria:

Boys will be excluded from HPV vaccination if:

• They have previously been vaccinated against HPV.

• They have a history of allergy or anaphylaxis to one or more of the HPV vaccine components, to yeast or to latex.

• They are enrolled in another vaccine research study that specifically specifies that they must not participate in a study of another vaccine

• They have been diagnosed with a chronic condition (except HIV, as per the comment above), such as an autoimmune condition, sickle cell disease, degenerative disease, neurologic or genetic disease, among others;

• There are significant conditions or clinically significant findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., it would compromise their safety or well-being).

Related Conditions & MeSH terms

• HPV Infection
• Papillomavirus Infections
• Vaccine Preventable Disease

Intervention

Biological:
• Gardasil® HPV vaccine
Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).

Locations

Country	Name	City	State
Tanzania	Mwanza Intervention Trials Unit	Mwanza

Sponsors (6)

Lead Sponsor	Collaborator
London School of Hygiene and Tropical Medicine	Cancer Epidemiology Research Programme Institut Català d' Oncologia, Department of Pathology University of Cambridge, Karolinska Institute Department of Laboratory Medicine, Mwanza Intervention Trials Unit, National Institute for Medical Research, York Biomedical Research Institute, Hull York Medical School, University of York

Country where clinical trial is conducted

Tanzania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Impact of adding single-dose male HPV vaccination to the national HPV vaccination programme in girls on population 4-valent HPV genotype prevalence in 18 to 21-year-old females and males	Prevalence of 4-valent vaccine HPV genotype DNA (HPV 6, 11, 16 or 18) in males and females aged 18 to 21 years in intervention clusters and control clusters 36 months post-male vaccination	Month 36
Secondary	Immunogenicity and safety of single dose 4-valent HPV vaccination in boys	Proportion seroconverting to, and geometric mean antibody titres (GMTs) for, HPV vaccine genotypes, and safety and tolerability (local and systemic adverse events), measured in a subset of 200 vaccinated boys	Month 12, 24 and 36
Secondary	Impact of female-only vaccination through the national vaccination programme on population HPV prevalence in 18 to 21-year-old males and females	The proportion of females, and of males, aged 18 to 21 years in the control arm with detectable genital 4-valent HPV vaccine genotype DNA at baseline and at M36.	Month 36
Secondary	Uptake of dose 1 and coverage of dose 2 in eligible target groups for the national HPV vaccination programme;	The proportion of females aged 16 years who received 1 dose of HPV vaccine (uptake) and who complete 2 doses (coverage) by arm at baseline and M36	Month 36
Secondary	Acceptability of a gender-neutral approach to HPV vaccination	Self-reported acceptability of and barriers to receiving male vaccination by community members and to delivering male HPV vaccination by health care workers (HCW)	Month 24
Secondary	Cost-effectiveness of adding a multi-year single dose male HPV vaccination strategy to the national female HPV vaccination programme	Incremental cost-effectiveness ratio for single dose male vaccination plus existing female vaccination programme compared to female vaccination only	Month 36